AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of …
February 3, 2010 by Midas
Filed under Spa Treatment
AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of …
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr. Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUEBEC CITY, Feb. 3 /PRNewswire-FirstCall/ – AEterna Zentaris Inc.
Read more on redOrbit
Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind …
January 26, 2010 by Midas
Filed under Spa Treatment
Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind …
Keryx Biopharmaceuticals, Inc. yesterday reported updated results on the clinical activity of KRX-0401 , the Company’s PI3K/Akt pathway inhibitor for cancer, in combination with capecitabine as a treatment for advanced, metastatic colon cancer. Abstract #447, entitled, “Randomized phase II study of [...]
